Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

gemopatrilat

Known as: (6S)-Hexahydro-6-((alphaS)-alpha-mercaptohydrocinnamamido)-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
This study describes the pharmacokinetic parameters of gemopatrilat, a potent vasopeptidase inhibitor, in humans and the… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2006
2006
This study describes the pharmacokinetic parameters of gemopatrilat, a potent vasopeptidase inhibitor, in humans and the… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2003
2003
BACKGROUND Control of blood pressure (BP) and optimal reduction of proteinuria (Uprot) are necessary for long-term renoprotection… Expand
Is this relevant?
Review
2002
Review
2002
  • G. Sagnella
  • Journal of the renin-angiotensin-aldosterone…
  • 2002
  • Corpus ID: 24479593
Vasopeptidase inhibitors are a new class of drugs that have dual inhibitory effects on two key enzymes involved in the metabolism… Expand
Is this relevant?
Review
2002
Review
2002
Vasopeptidase inhibitors are a new class of drugs that have dual inhibitory effects on two key enzymes involved in the metabolism… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
2001
2001
Objectives Vasopeptidase inhibitors are single molecules that simultaneously inhibit neutral endopeptidase (NEP) and angiotensin… Expand
Is this relevant?